Replies to post #160666 on Biotech Values

[genisi]

Are you also significantly less optimistic about AGN's dual-acting (VEGF/PDGF) DARPin in preclinical development? According to yesterday's CC, the plans and timeline for this drug haven't changed at all, but this assertion might include a modicum of spin.

Of course I'll be more confidant when I see DARPin's phase IIb data, but I don't think safety was the issue, and as for efficacy the dual DARPin has theoretically a better shot to begin with, so for now I'm not less optimistic about it.